Waddell & Reed Financial’s Acceleron Pharma XLRN Stock Holding History

Waddell & Reed Financial’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-49,337	Closed	-$4.7M	–	488
2020 Q2	$4.7M	Buy	+49,337	New	+$4.76M	0.01%	427
2018 Q3	–	Sell	-28,300	Closed	-$1.37M	–	584
2018 Q2	$1.37M	Hold	28,300	–	–	﹤0.01%	522
2018 Q1	$1.11M	Buy	+28,300	New	+$1.2M	﹤0.01%	513

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Waddell & Reed Financial's XLRN Position: Q3 2020 in Review

Waddell & Reed Financial sold out of Acceleron Pharma (XLRN) in Q3 2020, closing a stake of 49,337 shares — an estimated $4.7M sold.

Waddell & Reed Financial first reported a position in XLRN in Q1 2018 and held it in 3 quarters. The position peaked at $4.7M in Q2 2020. 238 funds tracked by Wall St. Rank hold XLRN as of Q3 2020.

Waddell & Reed Financial reported no remaining Acceleron Pharma position as of Q3 2020 after selling out during the quarter.
Waddell & Reed Financial sold 49,337 Acceleron Pharma shares in Q3 2020, an estimated $4.7M.
Waddell & Reed Financial first reported a position in Acceleron Pharma in Q1 2018 and held it in 3 quarters.
Waddell & Reed Financial's Acceleron Pharma position peaked at $4.7M in Q2 2020.
238 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2020.

Based on Waddell & Reed Financial's 13F filing for Q3 2020, filed 13 Nov 2020.